Related Experiment Video
Updated: Oct 10, 2025
09:42
Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research
Published on: April 19, 2017
7.6K
IOX1 impedes host inflammation in imiquimod-triggered psoriasis
Joo Eun Shin1, Su Jin Lee1, Amal Gharbi2
1Department of Immunology, Laboratory of Dendritic Cell Differentiation & Regulation, School of Medicine, Konkuk University, Chungju 380-701, Seoul, South Korea.
Heliyon
|December 8, 2021
Summary
8-hydroxyquinoline-5-carboxylic acid (IOX1) shows therapeutic potential for psoriasis. This novel drug reduced inflammation and improved scores in a mouse model, offering a promising new treatment option.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Psoriasis is a chronic autoimmune skin disease with limited long-term treatment options due to severe side effects.
- Epigenetic modifications are emerging therapeutic targets for psoriasis, but their role remains largely unexplored.
Purpose of the Study:
- To investigate the therapeutic potential of 8-hydroxyquinoline-5-carboxylic acid (IOX1) in a mouse model of psoriasis.
- To evaluate the efficacy of IOX1 in reducing inflammation and improving disease indicators.
Main Methods:
- A mouse model of imiquimod (IMQ)-induced psoriatic inflammation was used.
- IOX1 was administered topically and intraperitoneally.
- Key indicators assessed included skin inflammation, PASI score, pro-inflammatory cytokine mRNA levels, splenocyte populations, and macrophage polarization.
Main Results:
- Topical IOX1 reduced skin inflammatory reactions and lowered the Psoriasis Area and Severity Index (PASI) score.
- Intraperitoneal IOX1 repressed systemic inflammation by decreasing pro-inflammatory cytokines, restoring splenocyte balance, and regulating macrophage polarization.
Conclusions:
- IOX1 demonstrates significant remedial effects on dermatitis psoriasis in a preclinical model.
- IOX1 holds potential as a novel therapeutic compound for managing psoriasis, possibly through epigenetic mechanisms.
Related Concept Videos
01:24T Cell Types and Functions
1.5K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.5K
01:28Inflammatory Response
11.2K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
11.2K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
256
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
256
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
284
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
284